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The policies of the US Food and Drug Administration (FDA) will affect the developmental course of any therapeu-
tic, diagnostic, or preventative agent aimed 
at being marketed in the United States. As 
such, the FDA impacts almost all translational 
research. Put more bluntly, no research will be 
translated as a product to the US medical mar-
ket until it is approved by the FDA. 
I wrote a book entitled The FDA for Doctors 
(Eaglstein, 2014), which was recently published 
by Springer, said to be the largest academ-
ic press in the world. I had been working on 
the book episodically for some years and had 
a hard time finding a publisher. Several pub-
lishers of medical books declined, believing 
the book would not be of interest to doctors. 
The publishers explained that they succeed by 
publishing cardiology books for cardiologists, 
endocrinology books for endocrinologists, 
dermatology books for dermatologists, and so 
forth. They felt a book on the FDA, because it 
was not focused on a given specialty, would 
not be purchased by doctors. For specialists 
engaged in translational research, I strongly dis-
agree.  
My more-than-casual interest in the FDA 
first came through performing clinical stud-
ies aimed at FDA approval. I later helped with 
the FDA’s long-delayed review of the efficacy 
of drugs approved for marketing before effi-
cacy was required, the so-called Drug Efficacy 
Study Implementation review. I have served as 
a member and ultimately the chair of FDA’s der-
matologic drug advisory committee, and when 
I was a Robert Wood Johnson Heath Policy 
Fellow, for a short time I was given the lead role 
in FDA oversight for the US Senate by way of 
the Labor Committee. During this time, I, too, 
decided that most doctors seem little interested 
in the FDA. I felt this disinterest was largely the 
result of doctors receiving limited formal train-
ing about the FDA while in medical school and 
then becoming overwhelmingly busy in the 
practice world. 
Why wouldn’t doctors be curious about an 
agency that determines which drugs, biologi-
cals, and medical devices can be sold in the 
United States, an agency that mandates what 
can and must be on the labels of all therapeu-
tics and what can be said to doctors and in 
advertisements? Few individuals realize that 
because of the FDA’s policies, the United States 
is one of only two countries that allow direct-
to-consumer drug advertising. The FDA must 
approve even a drug’s name before it can be 
sold, and its authority actually covers 25% of 
the US economy, including foods, drugs, bio-
logics, devices, cosmetics, and tobacco prod-
ucts. How many doctors know that the defini-
tional difference between a drug and a device 
is that devices do not act chemically? And that 
more than 95% of new medical devices receive 
FDA approval without any required human test-
ing? Although most doctors know that human 
clinical trials, phases I, II, and III, are required 
for drug approval, few realize that the clinical 
trials, especially phase III, are the most costly 
part of drug development. For completely new 
drugs, this cost is now estimated to be in the $2 
billion range (Tufts Center, 2014).
There are probably many reasons that doc-
tors are not more interested in an agency whose 
policies and regulations control so much of 
what we need to prevent, diagnose, and treat 
disease. For one thing, the practice of medicine 
is controlled by the states, which issue licens-
es to practice medicine. The FDA is a federal 
agency whose powers derive from the federal 
control over interstate sales. That is, the FDA 
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has no authority over the practice of medicine. As such, 
although science and medicine are often at the heart of 
FDA matters, the FDA’s powers, responsibilities, and actions 
derive mainly from laws and legal constructs that inherently 
reside in the legal rather than the medical purview.  
I recognize that many of the JID’s readers are not medi-
cal doctors. However, like medical doctors, academic and 
other researchers have received little formal education 
about the FDA. Most investigators, even basic scientists, 
aspire to have their work result in clinical application, even 
if that occurs sometime in the distant future. The JID’s edi-
tor, Barbara Gilchrest, selected “Progress in Translational 
Research” as the journal’s 2015 theme “to celebrate the 
impressive progress” in translational research (Gilchrest, 
2015). A subsequent editorial (Parrish et al., 2015) high-
lighted the need for academic investigators, physicians and 
nonphysicians alike, to be informed about the process of 
having their work translated to the clinic. The editorial gave 
as an example the need to forgo quick publication or pre-
sentation of findings to obtain patents, which are critical to 
incentivizing companies or venture capitalists to invest in 
the translational process.  
In a similar manner, and realizing that almost all trans-
lation to the bedside in the United States is dependent on 
FDA marketing approval, knowledge about the agency—
especially its regulatory categories and its preclinical as 
well as clinical requirements—will be useful in guiding 
researchers in directions that are most advantageous to the 
ultimate translation of their findings and technologies. For 
example, by knowing the difficulties of large-scale pro-
duction and characterization of large protein molecules 
made by microorganisms (biologics), investigators might 
at the earliest possible stage seek small molecules able to 
mimic the effect achieved with large molecules to have a 
potential small-molecule drug. Recognizing the need for 
a stable molecule might dispose researchers to select this 
criterion at the earliest stage. Knowledge of the definition 
and approval pathways for devices might dictate the use 
of certain experimental approaches and an alertness to 
devices already on the market that might serve as predi-
cates, thus greatly reducing the requirement for preapprov-
al clinical testing. Similarly, knowledge of regulatory cat-
egories such as combination drug–device and device–drug 
can be useful early in the game. Of course, much of the 
work involved in ultimately obtaining FDA approval, espe-
cially the chemistry, manufacturing, and control require-
ments and long-term toxicology, cannot usually be done by 
academic investigators. However, the insights afforded by 
knowing more about the process might well help to short-
en the “valley of death,” the period between the discovery 
of a potential drug and when the support for translational 
work is secured.
In summary, I believe that all medical scientists and phy-
sicians would not only help themselves but also ultimately 
help society by becoming more conversant with the FDA’s 
roles and its processes for carrying them out. It was with 
those beliefs in mind that my book was written. The book 
can serve as a primer for medical students, postdoctoral 
fellows pursuing medical research, and all those intrigued 
by translational research at any time in their careers. 
Information about the FDA and its goals, policies, and 
requirements can be found in many other places as well, 
including the agency’s websites.
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